NK-86-0279-II;44-HOMO-OLIGOMYCIN-A
Compound with spectra: 1 NMR
| SpectraBase Compound ID | Ev8KBi1F0dZ |
|---|---|
| InChI | InChI=1S/C46H76O11/c1-12-34-18-16-14-15-17-28(5)43(52)45(11,54)44(53)33(10)41(51)32(9)40(50)31(8)39(49)27(4)19-22-38(48)55-42-30(7)36(21-20-34)56-46(35(42)13-2)24-23-26(3)37(57-46)25-29(6)47/h14-16,18-19,22,26-37,39,41-43,47,49,51-52,54H,12-13,17,20-21,23-25H2,1-11H3/b15-14+,18-16+,22-19+/t26-,27-,28+,29+,30+,31-,32-,33-,34-,35-,36-,37+,39+,41+,42+,43-,45+,46-/m1/s1 |
| InChIKey | APJPYXAUMOLFTM-KBMJDHDHSA-N |
| Mol Weight | 805.1 g/mol |
| Molecular Formula | C46H76O11 |
| Exact Mass | 804.538763 g/mol |
| Enantiomer InChIKey | APJPYXAUMOLFTM-RXOYHREGSA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CDCl3 |
LL-F28249-OMEGA;21-HYDROXYOLIGOMYCIN_A
,10,2',3',4'-PENTA-O-ACETYL-6'-O-TERT.-BUTYLDIMETHYLSILYLAUCUBIN
29-EPI-RAPAMYCIN
5,7-Ergostadiene-1.alpha.,3.beta.,25-triol
Methyl 7-(2-(3-trimethysiloxy-1-octenyl)-3-methoxyimino-5-trimethylsiloxycyclopentyl)hept-5(Z)-enoate-5,6,8,9,12,14,15-D7
3-Acetoxy-16-[[(2'-acetoxyethyl)acetylamino]methylene}-5,alpha.-androstan-17-one
CLONOSTACHIN;AC-AIB-1-L-HYP-2-L-LEU-3-D-IVA-4-L-HYP-5-L-LEU-6-L-IVA-7-L-HYP-8-AIB-9-L-IVA-10-AIB-11-L-HYP-12-D-IVA-13-L-ILE-14-MANNITOL
FLEXUOSIN B
TAN-1323-C
thiazolo[3,2-a]benzimidazol-3(2H)-one, 2-[(1-acetyl-3-phenyl-1H-pyrazol-4-yl)methylene]-7,8-dimethyl-, (2E)-
| Title | Journal or Book | Year |
|---|---|---|
| 44-Homooligomycins A and B, new antitumor antibiotics from Streptomyces bottropensis. Producing organism, fermentation, isolation, structure elucidation and biological properties. | The Journal of Antibiotics | 1992 |
This compound is available in the following databases:
KnowItAll NMR Spectral Library
Author: Wiley
The KnowItAll NMR Spectral Library offers a comprehensive collection of NMR reference spectra, including NMR, CNMR, and XNMR, and covers a wide range of compounds including organics, polymers, monomers, metabolites, and more. Learn more.